2021
DOI: 10.1016/j.jval.2021.04.272
|View full text |Cite
|
Sign up to set email alerts
|

PCN181 Real-World Evidence (RWE) in Reimbursement, Pricing, and Health Technology Assessment (HTA) in ASIA. How CAN Rwe Supplement Trial DATA in Oncology Indications in a Premarketing Setting?

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles